Taipei Exchange - Delayed Quote TWD

MegaPro Biomedical Co., Ltd (6827.TWO)

Compare
14.45
+0.35
+(2.48%)
At close: 9:28:55 AM GMT+8

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.
NameTitlePayExercisedYear Born
Dr. Jassy Wang Chief Exec. Officer -- -- --

MegaPro Biomedical Co., Ltd

No. 66, Shengyi 5th Rd.
10th floor-1
Zhubei, 302
Taiwan
886 3 591 0360 https://www.megaprobio.com
Sector: 
Healthcare
Industry: 
Biotechnology

Description

MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in preclinical trial for the treatment of malignant tumor. The company was founded in 2014 and is based in Zhubei, Taiwan.

Corporate Governance

MegaPro Biomedical Co., Ltd’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers